Idasanutlin: Clinical Trials

9 trials of Idasanutlin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 terminated, 2 completed. 9 Phase 2, 8 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Terminated 7, Completed 2
Phase 18Terminated 6, Completed 2

Follow Idasanutlin: new trials by email Literature Review of Idasanutlin trials Research Report on Idasanutlin

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Idasanutlin, Venetoclax, Cyclophosphamide - Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Phase 1 / Phase 2TerminatedHoffmann-La Roche382020-01-272024-12-20
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Idasanutlin, Cytarabine, Daunorubicin - Acute Myeloid Leukemia
Phase 1 / Phase 2TerminatedHoffmann-La Roche242019-03-252022-06-21
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)
Regorafenib, Atezolizumab, Imprime PGG - Colorectal Cancer
Phase 1 / Phase 2TerminatedHoffmann-La Roche962018-09-272023-11-07
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Atezolizumab, Cobimetinib, Idasanutlin - Stage III Breast Cancer, Stage IIIA Breast Cancer
Phase 1 / Phase 2TerminatedVanderbilt-Ingram Cancer Center122018-07-102021-08-11
NCT Neuro Master Match - N²M² (NOA-20)
APG101, Alectinib, Idasanutlin - Glioblastoma, Adult
Phase 1 / Phase 2CompletedUniversity Hospital Heidelberg2282018-05-072023-09-28
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Idasanutlin - Polycythemia Vera
Phase 2TerminatedHoffmann-La Roche272018-02-212021-12-08
A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)
Idasanutlin, Obinutuzumab, Venetoclax - Follicular Lymphoma, Lymphoma, Large B-Cell, Diffuse
Phase 1 / Phase 2TerminatedHoffmann-La Roche292017-06-152021-12-07
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Dexamethasone, Idasanutlin, Ixazomib Citrate - Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
Phase 1 / Phase 2CompletedMayo Clinic332015-12-302024-09-19
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
Idasanutlin, Obinutuzumab, Rituximab - Non-Hodgkin's Lymphoma
Phase 1 / Phase 2TerminatedHoffmann-La Roche252015-12-232020-05-18

Conditions studied

Leukemia, Myeloid, Acute (2)  ·  Breast Neoplasms (1)  ·  Chromosome 17 deletion (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)  ·  Hematologic Diseases (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Multiple Myeloma (1)  ·  Myeloproliferative Disorders (1)  ·  Neuroblastoma (1)  ·  Polycythemia Vera (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)

Sponsors

Hoffmann-La Roche (6)  ·  Mayo Clinic (1)  ·  University Hospital Heidelberg (1)  ·  Vanderbilt-Ingram Cancer Center (1)

Countries

United States (8)  ·  Australia (5)  ·  France (3)  ·  Germany (3)  ·  South Korea (3)  ·  Canada (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Spain (2)  ·  Netherlands (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Ingrid Mayer, MD (1)  ·  Shaji Kumar, M.D. (1)  ·  Wolfgang Wick, Prof. Dr. (1)

Results publications

PMID 34933330, PMID 40913172, PMID 41379293

NIH funding

2015 (2), 2017 (2), 2018 (2), 2016 (1)